Central nervous system involvement in diffuse large B-cell lymphoma

European Journal of Haematology

Volumn 85, Issue 1, 2010, Pages 6-10

  Yamamoto, Wataru ^a,b   Tomita, Naoto ^c   Watanabe, Reina ^c   Hattori, Yukako ^d   Nakajima, Yuki ^e   Hyo, Rie ^f   Hashimoto, Chizuko ^g   Motomura, Shigeki ^g   Ishigatsubo, Yoshiaki ^c  

^a Yamato Municipal Hospital   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d SHIZUOKA RED CROSS HOSPITAL   (Japan)

^e Yokosuka City Hospital   (Japan)

^f Fujisawa City Hospital   (Japan)

^g KANAGAWA CANCER CENTER   (Japan)

Author keywords

Central nervous system; Diffuse large B cell lymphoma; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CENTRAL NERVOUS SYSTEM; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROPHYLAXIS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; VINCRISTINE;

EID: 77953867584     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01438.x     Document Type: Article

References (16)

1. Tomita N, Kodama F, Kanamori H, Motomura S, Ishigatsubo Y. Secondary central nervous system lymphoma. Int J Hematol 2006 84 : 128 135.
2. van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma 2008 49 : 52 8.
3. Feugier P, Virion JM, Tilly H, et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004 15 : 129 133.
4. Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 2009 89 : 577 583.
5. Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2009 (in press).
6. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002 346 : 235 242.
7. Kikuchi A, Kawada H, Iwaki Y, Machida S, Tsuchiya T, Fukuda R, Hotta T. Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma. Rinsho Ketsueki 2004 45 : 1255 1257.
8. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993 329 : 987 994.
9. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971 31 : 1860 1861.
10. Zinzani PL, Magagnoli M, Frezza G, Prologo G, Gherlinzoni F, Bendandi M, Albertini P, Babini L, D'Alessandro R, Tura S. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma 1999 32 : 571 576.
11. Boehme V, Schmitz N, Zeynalova S, Loeffler M, Pfreundschuh M. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009 113 : 3896 3902.
12. van Besien K, Ha CS, Murphy S, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998 91 : 1178 1184.
13. Lee KW, Yi J, Choi IS, et al. Risk factors for poor treatment outcome and central nervous system relapse in diffuse large B-cell lymphoma with bone marrow involvement. Ann Hematol 2009 88 : 829 838.
14. Björkholm M, Hagberg H, Holte H, et al. Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up. Ann Oncol 2007 18 : 1085 1089.
15. Tomita N, Kodama F, Sakai R, et al. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations. Leuk Lymphoma 2000 38 : 335 343.
16. Quijano S, López A, Manuel Sancho J, et al. Identification of leptomeningeal disease in aggressive B-Cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol 2009 27 : 1462 1469.